Carregant...
Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced (V600E/K)BRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with (V600E/K)BRAF may be selected for by BRAFi. We sequenced MEK1/2 exon 3 in me...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3594852/ https://ncbi.nlm.nih.gov/pubmed/22588879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0022 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|